Baicalin Attenuates Laser-Induced Choroidal Neovascularization

Yang, Seung Min; Jo, Hyoung; Kim, June-Gone; Jung, Sang Hoon

doi:10.3109/02713683.2013.868908

Cited by 13 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To provide in vivo evidence with regard to this issue and define the role of baicalin in ocular tissue, the experiments conducted in this study used an oxygen-induced retinopathy model. Similar to our observations, a previous study used a laser-induced choroidal neovascular model to show that intravitreal injection of baicalin effectively attenuates choroidal neovascularization (9) . Although intravitreal injection is one of the most effective ways to deliver baicalin to the tissue, this invasive procedure carries several risks and complications.…”

Section: Discussionsupporting

confidence: 89%

The effect of baicalin in a mouse model of retinopathy of prematurity

Jo¹,

Jung²,

Yim³

et al. 2015

BMB Reports

Self Cite

View full text Add to dashboard Cite

Baicalin is a flavonoid derived from the dried root of Scutellaria baicalensis. In this study, oxygen-induced retinopathy was used to characterize the anti-angiogenic properties of baicalin in mice. Pups were exposed to a hyperbaric oxygen environment to induce retinal angiogenesis and were subjected to intraperitoneal injection of baicalin. Avascular area, neovascular tufts, and neovascular lumens were quantified from digital images. Compared to the vehicle, baicalin clearly reduced the central avascular zone and the number of neovascular tufts and lumens. High-dose baicalin (10 mg/kg) significantly reduced the expression of matrix metalloproteinase-2 (MMP-2), MMP-9, angiotensin II, and vascular endothelial growth factor (VEGF). These results show that baicalin is a powerful antiangiogenic compound that attenuates new vessel formation in the retina after systemic administration, and is a candidate substance for therapeutic inhibition of retinal angiogenesis. [BMB Reports 2015; 48(5): 271-276]

show abstract

Section: Discussionsupporting

confidence: 89%

The effect of baicalin in a mouse model of retinopathy of prematurity

Jo¹,

Jung²,

Yim³

et al. 2015

BMB Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…The transcript levels of several angiogenic factors, including VEGF, insulin-like growth factor (IGF)-1, angiopoietin (Ang)-2, FGF-2, and platelet-derived growth factor (PDGF)-B, are increased in mouse models of CNV. [32][33][34][35] The effects of UPARANT on angiogenic factor transcripts were investigated. As illustrated in Figure 6, after laser treatment, the levels of VEGF, IGF-1, Ang-2, FGF-2, and PDGF-B were increased by approximately 1.9-, 1.6-, 2.1-, 2.1-, and 1.9-fold, respectively (P < 0.001).…”

Section: Uparant Reduces the Expression Of Angiogenic Factorsmentioning

confidence: 99%

The Urokinase Receptor-Derived Peptide UPARANT Mitigates Angiogenesis in a Mouse Model of Laser-Induced Choroidal Neovascularization

Cammalleri

Monte

Locri

et al. 2016

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…Both the flavone glycoside baicalin, found in several plant species of the genus Scutellaria , and the natural flavone luteolin, abundantly present in several plant products, including broccoli, pepper, thyme, and celery, display antiangiogenic properties in models of retinal neovascularization. Indeed, intravitreally-injected baicalin inhibits the growth of CNV in rats [172], while intravitreal luteolin has been reported to inhibit retinal neovascularization in the mouse OIR model and to suppress hypoxia-induced VEGF expression (via inhibition of HIF-1α) as well as VEGF-induced migration and tube formation in HRMECs [173]. Similarly to baicalin and luteolin, deguelin, a derivative of the isoflavonoid rotenone and a naturally occurring insecticide isolated from plants of the Mundulea sericea family, effectively reduces both CNV and OIR neovascularization [174,175].…”

Section: Nutraceuticals and Vascular Changesmentioning

confidence: 99%

Nutraceuticals for the Treatment of Diabetic Retinopathy

Rossino

Casini

2019

Nutrients

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is one of the most common complications of diabetes mellitus and is characterized by degeneration of retinal neurons and neoangiogenesis, causing a severe threat to vision. Nowadays, the principal treatment options for DR are laser photocoagulation, vitreoretinal surgery, or intravitreal injection of drugs targeting vascular endothelial growth factor. However, these treatments only act at advanced stages of DR, have short term efficacy, and cause side effects. Treatment with nutraceuticals (foods providing medical or health benefits) at early stages of DR may represent a reasonable alternative to act upstream of the disease, preventing its progression. In particular, in vitro and in vivo studies have revealed that a variety of nutraceuticals have significant antioxidant and anti-inflammatory properties that may inhibit the early diabetes-driven molecular mechanisms that induce DR, reducing both the neural and vascular damage typical of DR. Although most studies are limited to animal models and there is the problem of low bioavailability for many nutraceuticals, the use of these compounds may represent a natural alternative method to standard DR treatments.

show abstract

Baicalin Attenuates Laser-Induced Choroidal Neovascularization

Abstract: Baicalin suppressed laser-induced CNV formation in rats. These results suggest that baicalin should be considered as a candidate drug for treating exudative age-related macular degeneration.

Cited by 13 publications

References 38 publications

The effect of baicalin in a mouse model of retinopathy of prematurity

The effect of baicalin in a mouse model of retinopathy of prematurity

The Urokinase Receptor-Derived Peptide UPARANT Mitigates Angiogenesis in a Mouse Model of Laser-Induced Choroidal Neovascularization

Nutraceuticals for the Treatment of Diabetic Retinopathy

Contact Info

Product

Resources

About